Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.

Baek G, Varma G, Yamshon S, van Besien H, Bartlett NL, Watkins M, Shah HR, Baron K, Merryman RW, Falade AS, Svoboda J, Prischak S, D'Angelo C, Lukowski JD, Advani RH, Yeung AH, Rosenberg M, Voutsinas J, Di M, Lynch R, Poh C, Raghunathan V, Shadman M, Smith S, Till BG, Ujjani C, Diefenbach CS, Gopal AK

Open source

DOI: 10.1182/bloodadvances.2025018267
Published: 2026 May 26
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025018267,
  title = {Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.},
  author = {Baek G and Varma G and Yamshon S and van Besien H and Bartlett NL and Watkins M and Shah HR and Baron K and Merryman RW and Falade AS and Svoboda J and Prischak S and D'Angelo C and Lukowski JD and Advani RH and Yeung AH and Rosenberg M and Voutsinas J and Di M and Lynch R and Poh C and Raghunathan V and Shadman M and Smith S and Till BG and Ujjani C and Diefenbach CS and Gopal AK},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2025018267},
  url = {https://doi.org/10.1182/bloodadvances.2025018267}
}

RIS

TY  - JOUR
TI  - Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.
AU  - Baek G
AU  - Varma G
AU  - Yamshon S
AU  - van Besien H
AU  - Bartlett NL
AU  - Watkins M
AU  - Shah HR
AU  - Baron K
AU  - Merryman RW
AU  - Falade AS
AU  - Svoboda J
AU  - Prischak S
AU  - D'Angelo C
AU  - Lukowski JD
AU  - Advani RH
AU  - Yeung AH
AU  - Rosenberg M
AU  - Voutsinas J
AU  - Di M
AU  - Lynch R
AU  - Poh C
AU  - Raghunathan V
AU  - Shadman M
AU  - Smith S
AU  - Till BG
AU  - Ujjani C
AU  - Diefenbach CS
AU  - Gopal AK
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2025018267
UR  - https://doi.org/10.1182/bloodadvances.2025018267
ER  -

APA

G, B., G, V., S, Y., H, V. B., NL, B., M, W., HR, S., K, B., RW, M., AS, F., J, S., S, P., C, D., JD, L., RH, A., AH, Y., M, R., J, V., M, D., R, L., C, P., V, R., M, S., S, S., BG, T., C, U., CS, D., & AK, G. (2026). Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.. Blood advances. https://doi.org/10.1182/bloodadvances.2025018267

Source records

pubmed · retrieved 2026-09-26T21:04:09.318Z
europe-pmc · retrieved 2026-09-26T21:04:09.326Z